Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology Pinecast (https://pinecast.com) en-US@Point of Care @Point of Care atpointofcare@gmail.com false Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology https://storage.pinecast.net/podcasts/covers/54dff532-909d-4fc8-852b-66c58aef3572/HematologyOncology.png episodic Copyright 2020 At Point of Care, LLC. All rights reserved. https://pinecast.com/feed/oncology-point-of-care-podcast S36:E3 – Recognizing and Managing DLL3-Related Toxicities https://pinecast.com/guid/675f3bb0-d784-4ff9-9793-96ba7df6a9af Tue, 29 Sep 2026 01:01:43 -0000 00:28:58 https://www.atpointofcare.com/library/2759.03/page/0 How can clinicians safely navigate cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome associated with delta-like ligand 3-directed T-cell engagers? Join Dr. Nisha Mohindra and Dr. Rahul Aggarwal as they discuss recognizing, grading, and managing these toxicities, along with practical strategies for monitoring, risk mitigation, multidisciplinary care, and patient and caregiver education.

Visit https://www.atpointofcare.com/library/2759.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Recognizing and Managing DLL3-Related Toxicities false 36 3 S36:E2 – Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care https://pinecast.com/guid/7d604467-3b68-4cc0-af86-062a8f4f16e0 Tue, 29 Sep 2026 00:48:41 -0000 00:22:18 https://suitehome.atpointofcare.com/library/2746.02/page/0 RAS-targeted therapies are reshaping the treatment landscape for pancreatic ductal adenocarcinoma, creating new challenges in understanding the mechanisms and potential clinical applications of allele-specific, pan-KRAS, and pan-RAS inhibitors. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they explore the evolving RAS therapeutic pipeline and discuss how these emerging strategies may inform future treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2746.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care false 36 2 S36:E1 – Differentiating Neuroendocrine Tumors (NETs) From Neuroendocrine Carcinomas (NECs) https://pinecast.com/guid/489c4fb6-6551-429a-9329-9cf93e7a60c6 Tue, 29 Sep 2026 00:42:51 -0000 00:19:28 https://www.atpointofcare.com/library/2759.01/page/0 When does a neuroendocrine tumor warrant a second look? Join Dr. Nisha Mohindra and Dr. Rahul Aggarwal as they explore the clinical, imaging, and pathologic clues that distinguish neuroendocrine tumors from neuroendocrine carcinomas. Learn how multidisciplinary assessment, pathology review, and repeat biopsy can help resolve diagnostic uncertainty in challenging cases.

Visit https://www.atpointofcare.com/library/2759.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Differentiating Neuroendocrine Tumors (NETs) From Neuroendocrine Carcinomas (NECs) false 36 1 S35:E2 – Integrating Oral SERDs into the Management of HR+/HER2- Advanced Breast Cancer https://pinecast.com/guid/b8a1894c-a017-4c86-96a2-048600a21978 Tue, 22 Sep 2026 15:15:00 -0000 00:30:04 Explore the evolving role of oral SERDs in HR-positive, HER2-negative advanced breast cancer. Hear expert perspectives on ESR1 mutation testing, treatment selection and sequencing, emerging combination strategies, circulating tumor DNA (ctDNA) monitoring, and safety considerations that may inform individualized treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2760.12/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Integrating Oral SERDs into the Management of HR+/HER2- Advanced Breast Cancer false 35 2 S35:E1 – ESR1 Mutations in Advanced Breast Cancer: The Evolving Role of Oral SERDs https://pinecast.com/guid/5b87af6e-dc20-4b0c-be3a-177932845736 Tue, 22 Sep 2026 15:00:00 -0000 00:29:09 https://suitehome.atpointofcare.com/library/2760.11/page/0 Stay ahead of evolving endocrine resistance in HR-positive, HER2-negative advanced breast cancer. Discover how ESR1 mutations are reshaping treatment decisions, and explore expert perspectives on mutation testing, oral SERDs, and emerging serial monitoring strategies that may help identify resistance earlier and inform individualized patient care.

Visit https://suitehome.atpointofcare.com/library/2760.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> ESR1 Mutations in Advanced Breast Cancer: The Evolving Role of Oral SERDs false 35 1 S34:E3 – Special Considerations in the Management of Anal Cancer https://pinecast.com/guid/099f830f-c84a-46f0-9e13-53ddcc56d7ee Mon, 14 Sep 2026 14:45:00 -0000 00:24:59 https://www.atpointofcare.com/library/2750.03/page/0 Advance your approach to locally recurrent or metastatic anal cancer with expert, case-based insights into retifanlimab-based therapy, special patient populations, toxicity management, and care after progression. Learn how patient-specific factors can shape therapeutic decisions throughout the disease course—tune in now for practical perspectives you can apply in clinical practice.

Visit https://www.atpointofcare.com/library/2750.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Special Considerations in the Management of Anal Cancer false 34 3 S34:E2 – Implementing New Therapies for Anal Cancer: Focus on First-Line Combination Therapy in Locally Recurrent or Metastatic Disease https://pinecast.com/guid/06303bbc-7c60-4ef6-aeeb-b20cb6608274 Mon, 14 Sep 2026 14:30:00 -0000 00:27:45 https://www.atpointofcare.com/library/2750.02/page/0 Tune in to this podcast to refine your approach to locally recurrent or metastatic squamous cell carcinoma of the anal canal. Review the evidence for first-line retifanlimab plus carboplatin and paclitaxel, and gain practical insights to individualize treatment, optimize maintenance therapy, monitor safety, and integrate chemoimmunotherapy into clinical practice.

Visit https://www.atpointofcare.com/library/2750.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Implementing New Therapies for Anal Cancer: Focus on First-Line Combination Therapy in Locally Recurrent or Metastatic Disease false 34 2 S34:E1 – Early Recognition in Anal Cancer: Risk Factors and Referral Readiness https://pinecast.com/guid/44f15bec-dc6c-4a62-8dea-586ff0bbd607 Mon, 14 Sep 2026 14:00:00 -0000 00:29:36 https://www.atpointofcare.com/library/2750.01/page/0 Stay ahead in the evolving landscape of anal cancer care with this CME activity. Recognize patients at higher risk for squamous cell carcinoma of the anus (SCAC). Start the education and screening process with clarity, confidence, and compassion. Discover the latest expert recommendations on SCAC risk factors, diagnostic and referral steps, and effective patient communication.

Visit https://www.atpointofcare.com/library/2750.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Early Recognition in Anal Cancer: Risk Factors and Referral Readiness false 34 1 S33:E2 – Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care https://pinecast.com/guid/99a7614e-4d51-471d-b44f-01b0f5631d57 Wed, 09 Sep 2026 15:30:00 -0000 00:28:38 https://suitehome.atpointofcare.com/library/2746.02/page/0 RAS-targeted therapies are reshaping the treatment landscape for pancreatic ductal adenocarcinoma, creating new challenges in understanding the mechanisms and potential clinical applications of allele-specific, pan-KRAS, and pan-RAS inhibitors. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they explore the evolving RAS therapeutic pipeline and discuss how these emerging strategies may inform future treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2746.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care false 33 2 S33:E1 – Genomic Profiling in Pancreatic Cancer: From Guidelines to Practice https://pinecast.com/guid/2dfebf75-7391-490a-9905-f5cf9bf59f36 Tue, 08 Sep 2026 15:00:00 -0000 00:29:58 https://suitehome.atpointofcare.com/library/2746.01/page/0 As biomarker-directed therapies expand in pancreatic ductal adenocarcinoma, comprehensive genomic profiling is becoming increasingly important for identifying actionable alterations and informing treatment decisions. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they discuss when and how to perform genomic profiling, interpret key findings, and address practical challenges to obtaining clinically useful molecular information.

Visit https://suitehome.atpointofcare.com/library/2746.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Genomic Profiling in Pancreatic Cancer: From Guidelines to Practice false 33 1